C1-Esterase Inhibitor (Human) and Mitoxantrone Hydrochloride

• Generic Name: C1 esterase inhibitor (human)
• Dosage Forms: n.a.
• Other Brand Names: Berinert, Cinryze, Haegarda, Ruconest

Routine prophylaxis against angioedema attacks in adults and adolescents with hereditary angioedema (HAE). Designated an orphan drug by FDA for this use.

One of several agents that may be considered for long-term prophylaxis of HAE attacks; other drugs include attenuated androgens (e.g., danazol) and antifibrinolytic agents (e.g., tranexamic acid).

Consider long-term prophylaxis in patients with HAE who have frequent or severe attacks of angioedema; individualize need for prophylactic therapy based on factors such as severity of disease, frequency of attacks, patient's quality of life, availability of resources, and patient response to on-demand therapy.

Treatment of acute abdominal, facial, or laryngeal attacks of HAE in adults and adolescents. Designated an orphan drug by FDA for this use.

Recommended by US and international consensus guidelines as one of several options for treatment of acute HAE attacks; other drugs include ecallantide (plasma kallikrein inhibitor) and icatibant (bradykinin B2-receptor antagonist).

• Generic Name: mitoxantrone
• Dosage Forms: n.a.
• Other Brand Names: Novantrone

Acute Myeloid Leukemia

A component of various chemotherapy regimens for remission induction in acute myeloid (myelogenous, nonlymphocytic) leukemia (AML, ANLL). AML includes acute promyelocytic, monocytic, myelomonocytic, megakaryoblastic, and erythroid leukemias.

Used in combination with other antineoplastic agents in consolidation therapy regimens following induction of complete remission.